Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor
- PDF / 1,035,795 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 90 Downloads / 203 Views
(2020) 2:11
Neurological Research and Practice
GUIDELINE
Open Access
Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society Hans-Christoph Diener1*, Stefanie Förderreuther2, Charly Gaul3, Florian Giese4, Till Hamann5, Dagny Holle-Lee6, Tim P. Jürgens5, Katharina Kamm7, Torsten Kraya8, Christian Lampl9, Arne May10, Uwe Reuter11, Armin Scheffler12 and Peer Tfelt-Hansen13
Abstract Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (Erenumab) or against CGRP (Eptinezumab, Fremanezumab, Galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options, which already exist in migraine prevention. In randomized, placebo-controlled studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are provided for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions on the use of this new substance group are discussed. This guideline is an abridged and translated version of the guideline published by Diener H-C, May A et al., Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor, Supplement to S1 Guideline Therapy of Migraine Attack and Prevention of Migraine, 2019, Deutsche Gesellschaft für Neurologie (eds.), Guidelines for Diagnostics and Therapy in Neurology. A complete version of this guideline can be found on the website of the Deutsche Gesellschaft für Neurologie (www.dgn.org/leitlinien) and the AWMF (Arbeitsgemeinschaft wissenschaftlicher Medizinischer Gesellschaften). This guideline has been approved by the German Neurological Society (DGN) and the German Migraine and Headache Society (GMHS) and was reviewed by the two societies. Keywords: Episodic migraine, Chronic migraine, Migraine prevention, CGRP, Monoclonal antibodies, Guideline
* Correspondence: [email protected] 1 Medizinische Fakultät der Universität Duisburg-Essen, Institut für Medizinische Informatik, Biometrie und Epidemiologie (IMIBE), Hufelandstr. 26, 45147 Essen, Germany Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unles
Data Loading...
